# Shenzhen Enduring Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-enduring-biotech

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.shenzhenenduring.com
- Latest round: Series A (Oct 20, 2021)
- Investors on record: 5

## About

Based in Shenzhen, China, and established in 2018, Shenzhen Enduring Biotech LTD. is a drugs developer that focuses on developing innovative bispecific antibody therapeutics and biobetter medicines. The company was established by scientists from pharmaceutical companies and academic institute. The founders of the company come from several different yet complementary scientific disciplines in the drug development industry and who are inventors of numerous patents.

The company product lines include double antibody, double antibody drug conjugate (ADC), used the technology of dual-target pegylation, which JY108 of double antibody can be used to treat autoimmune diseases. The company developed patented technology of double site-specific bispecific antibody (DSP-BsAb), which could be used to bispecific antibody therapeutics for cancer immunotherapy as well as for combination therapy with synergistic effect. 

The company plans to accelerate to apply JY108 bi-antibody investigational new drug (IND), develop early research of new project, build preparation of pilot sites, and expand team.

## Funding rounds

- Series A, Oct 20, 2021 — Share Capital, Shenzhen Guozhong Venture Capital, Dunhong Capital Management, Leimerious, Chengdu Tianfu Sanjiang Asset Management
- Angel, Mar 21, 2019 — Share Capital

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Angel, Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Dunhong Capital Management (https://capitalatlas.ai/funds/dunhong-capital-management) — Series A
- Leimerious — Series A
- Chengdu Tianfu Sanjiang Asset Management — Series A